These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
5. Current approaches to the identification and management of breakthrough disease in patients with multiple sclerosis. Rudick RA; Polman CH Lancet Neurol; 2009 Jun; 8(6):545-59. PubMed ID: 19446274 [TBL] [Abstract][Full Text] [Related]
6. Treatment of relapsing-remitting multiple sclerosis: current approaches and unmet needs. Miller AE; Rhoades RW Curr Opin Neurol; 2012 Feb; 25 Suppl():S4-10. PubMed ID: 22398662 [TBL] [Abstract][Full Text] [Related]
7. Recognizing and treating suboptimally controlled multiple sclerosis: steps toward regaining command. Freedman MS; Cohen B; Dhib-Jalbut S; Jeffery D; Reder AT; Sandberg-Wollheim M; Weinstock-Guttman B Curr Med Res Opin; 2009 Oct; 25(10):2459-70. PubMed ID: 19678753 [TBL] [Abstract][Full Text] [Related]
8. Predicting and preventing the future: actively managing multiple sclerosis. Hutchinson M Pract Neurol; 2009 Jun; 9(3):133-43, discussion 144. PubMed ID: 19448055 [TBL] [Abstract][Full Text] [Related]
13. Current and future treatments for relapsing-remitting multiple sclerosis. Birnbaum G Curr Opin Drug Discov Devel; 2010 Mar; 13(2):214-25. PubMed ID: 20205055 [TBL] [Abstract][Full Text] [Related]
14. The Potential of Computational Modeling to Predict Disease Course and Treatment Response in Patients with Relapsing Multiple Sclerosis. Pappalardo F; Russo G; Pennisi M; Parasiliti Palumbo GA; Sgroi G; Motta S; Maimone D Cells; 2020 Mar; 9(3):. PubMed ID: 32121606 [TBL] [Abstract][Full Text] [Related]
15. Relapsing multiple sclerosis patients treated with disease modifying therapy exhibit highly variable disease progression: a predictive model. Scott TF; Hackett CT; Quigley MR; Schramke CJ Clin Neurol Neurosurg; 2014 Dec; 127():86-92. PubMed ID: 25459249 [TBL] [Abstract][Full Text] [Related]
16. Defining the response to multiple sclerosis treatment: the role of conventional magnetic resonance imaging. Rovaris M; Filippi M Neurol Sci; 2005 Dec; 26 Suppl 4():S204-8. PubMed ID: 16388359 [TBL] [Abstract][Full Text] [Related]
17. Use of therapies other than disease-modifying agents, including complementary and alternative medicine, by patients with multiple sclerosis: a survey study. Stoll SS; Nieves C; Tabby DS; Schwartzman R J Am Osteopath Assoc; 2012 Jan; 112(1):22-8. PubMed ID: 22302743 [TBL] [Abstract][Full Text] [Related]
18. Post-marketing survey on clinical response to interferon beta in relapsing multiple sclerosis: the Roman experience. Pozzilli C; Prosperini L; Sbardella E; De Giglio L; Onesti E; Tomassini V Neurol Sci; 2005 Dec; 26 Suppl 4():S174-8. PubMed ID: 16388353 [TBL] [Abstract][Full Text] [Related]
19. Emerging oral therapies for multiple sclerosis. Cohen BA; Rieckmann P Int J Clin Pract; 2007 Nov; 61(11):1922-30. PubMed ID: 17784852 [TBL] [Abstract][Full Text] [Related]